<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/621E4323-5F3F-488B-A1ED-D31C5A134CD5"><gtr:id>621E4323-5F3F-488B-A1ED-D31C5A134CD5</gtr:id><gtr:name>Puridify</gtr:name><gtr:address><gtr:line1>Basement Flat
93 Camden Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0HP</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/621E4323-5F3F-488B-A1ED-D31C5A134CD5"><gtr:id>621E4323-5F3F-488B-A1ED-D31C5A134CD5</gtr:id><gtr:name>Puridify</gtr:name><gtr:address><gtr:line1>Basement Flat
93 Camden Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0HP</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/782A4DB8-9169-46F8-8C93-1EE564C0EE63"><gtr:id>782A4DB8-9169-46F8-8C93-1EE564C0EE63</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Miller</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13078"><gtr:id>01D50B15-4BE7-43F3-90AF-5960CAD3EDD3</gtr:id><gtr:title>UCL Confidence in Concept 2013</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13078</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>700000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Evotec</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Holmes CiC collaboration with Evotec</gtr:description><gtr:id>72D443F8-8462-40AC-8200-3BEB39830AE4</gtr:id><gtr:impact>Collaboration led to the development of a Wellcome Trust SDDI application that had to be withdrawn at the full stage due to illness. The project team is seeking alternative approaches to exploiting the data package generated.
Multi-disciplinary - Chemistry, cheminformatics, biology, structural biology, clinical.</gtr:impact><gtr:outcomeId>56e14b984bdd23.97576939-1</gtr:outcomeId><gtr:partnerContribution>Provided high quality primary screening, medicinal chemistry and xray crystallography</gtr:partnerContribution><gtr:piContribution>Developed project proposal and plan. Provided theoretical and practical disease expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Puridify</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Nathwani CiC collaboration with Puridify</gtr:description><gtr:id>2EBBB68E-833F-40A8-AC9D-D33171809D5F</gtr:id><gtr:impact>Too early to be specific</gtr:impact><gtr:outcomeId>56e1519f105d42.96413175-1</gtr:outcomeId><gtr:partnerContribution>Technical expertise in the production and purification of AAV vectors</gtr:partnerContribution><gtr:piContribution>Development of the project proposal and plan. Theoretical, technical and practical biological and disease expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Gale CiC Collaboration with GSK</gtr:description><gtr:id>189BBBB4-E9E6-4F8D-98E7-EDE52A4D6BB9</gtr:id><gtr:impact>Project completed disproving published literature data.
The collaboration continues through the appointment of Rick Cousins (GSK) as a visiting professor to UCL.</gtr:impact><gtr:outcomeId>56e1466ca604b4.83764944-1</gtr:outcomeId><gtr:partnerContribution>In vitro compound screening and provision of modulator compounds</gtr:partnerContribution><gtr:piContribution>Project proposal around the development of notch pathway modulators in the treatment of hearing loss. Project team provides theoretical, technical and practical disease biology expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Mookerjee CiC collaboration with Medimmune</gtr:description><gtr:id>760DF463-9391-442A-94AA-D1538FE9F936</gtr:id><gtr:impact>Agreement with Medimmune to supply protein</gtr:impact><gtr:outcomeId>56e14f99cf6194.68792861-1</gtr:outcomeId><gtr:partnerContribution>Generation and scaled up preparation of a key rat isoform of the LCAT protein needed in the project.</gtr:partnerContribution><gtr:piContribution>Development of research project proposal and plan. Disease and biology expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>273288</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Research Training Fellowship</gtr:department><gtr:description>Wellcome Trust Clinical Training Fellopwship - O'brien/George</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A90319CA-095E-4A79-B2C8-3490AD93AE4E</gtr:id><gtr:outcomeId>56e16614a31f41.51007341</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>198000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gamma Healthcare - Day</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Gamma Healthcare</gtr:fundingOrg><gtr:id>2071AE05-3C81-4AF0-9C74-89ABED2AE854</gtr:id><gtr:outcomeId>56e166dc553df5.44351768</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>119BC576-418D-498B-B50F-EA46E52A6DB3</gtr:id><gtr:title>Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee84e71113646d7a36a4715452fa3bbe"><gtr:id>ee84e71113646d7a36a4715452fa3bbe</gtr:id><gtr:otherNames>Igoe N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5aa664c883e259.42711331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6878D90-ABEE-46C8-A6BF-9CCEAAEC1B6B</gtr:id><gtr:title>Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee84e71113646d7a36a4715452fa3bbe"><gtr:id>ee84e71113646d7a36a4715452fa3bbe</gtr:id><gtr:otherNames>Igoe N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5aa657770ac9a1.67116810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4CABFE0-73DB-4D6C-93E2-621816F355E9</gtr:id><gtr:title>4-Cyano-2-methoxybenzenesulfonyl Chloride</gtr:title><gtr:parentPublicationTitle>Organic Syntheses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430b1781ca49702563c863123f3145c1"><gtr:id>430b1781ca49702563c863123f3145c1</gtr:id><gtr:otherNames>Bayle E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa6631d4153b3.81589896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04E05A06-1B3C-4FCC-95D9-68E086B4683F</gtr:id><gtr:title>A Comparison of Human Neutrophils Acquired from Four Experimental Models of Inflammation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa34877485aafef3742a96902a442fcb"><gtr:id>fa34877485aafef3742a96902a442fcb</gtr:id><gtr:otherNames>Maini AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aa655d09d5418.00412437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D9E4CE2-B0FC-4CC5-A204-3880B2D19F77</gtr:id><gtr:title>Sustained antimicrobial activity and reduced toxicity of oxidative biocides through biodegradable microparticles.</gtr:title><gtr:parentPublicationTitle>Acta biomaterialia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36464daffd0a8f64e3fc2651cee5d25"><gtr:id>a36464daffd0a8f64e3fc2651cee5d25</gtr:id><gtr:otherNames>Sofokleous P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-7061</gtr:issn><gtr:outcomeId>5aa6566d0d7e78.02546998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>487B33D4-EFCB-411D-A0E9-924C4A72BBA1</gtr:id><gtr:title>Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d485d5538b9736a4445f38d0f15d51c"><gtr:id>8d485d5538b9736a4445f38d0f15d51c</gtr:id><gtr:otherNames>Meier JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>5aa66472acb128.49480110</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13078</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>